Australian (ASX) Stock Market Forum

NYR - Nyrada Inc.

System

Administrator
Joined
Jun 27, 2010
Posts
3,167
Reactions
81
Nyrada is a pre-clinical stage, drug development company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.

The Company's vision is to become a high growth bio-pharmaceutical company specialising in drug discovery and early stage drug development, based mainly around the benzopyran molecular scaffold and focusing on areas of substantial unmet clinical need, where few if any, effective or well-tolerated therapies exist.

The Company has four current drug development programs:
  • Cardiovascular: a PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
  • Neuroprotection: a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury
  • Inflammation/pain: a drug to treat pain associated with peripheral nerve damage, and
  • Inflammation/autoimmunity: a drug to treat autoimmune diseases such as psoriasis.
It is anticipated that NYR will list on the ASX during December 2019.

https://www.nyrada.com
 

Dona Ferentes

Baron Samedi
Joined
Jan 11, 2016
Posts
3,114
Reactions
3,288
From NOX announcement 18 Dec (slightly different):
The Boards of both Noxopharm Ltd (ASX:NOX) and Nyrada Inc are pleased to announce that commitments for the Maximum Subscription of $8,500,000 for the Nyrada Initial Public Offer (IPO) have been received.

The Company has been advised by the Lead Manager, Alto Capital, that the IPO Offer has been fully allocated and final reconciliation of funds are underway with formal closure of the Offer expected before Christmas. Nyrada can confirm that the Minimum Subscription of $7,000,000 has been received and is being held in trust.

Nyrada currently is in discussions with the ASX regarding confirmation of conditional approval requirements, however notes that further to recent ASX correspondence, conditional approval and an ASX listing of Nyrada is now expected in January 2020.

Nyrada is a U.S.-incorporated company established by Noxopharm in 2017 for the purpose of developing drugs across the three areas of cardiovascular, neurological and inflammatory diseases and disorders.
 
Thread starter Similar threads Forum Replies Date
D 360 - Life360 Inc Stocks 0-H 0
T TTZ - Total Telcom Inc. International Markets 0
T AXM - Axmin Inc. International Markets 0
D ZBT - Zebit, Inc. Stocks Q-Z 5

Similar threads

Top